REMARKS

Applicants respectfully request that the foregoing amendments to Claims 4, 6-8, 10, 13, 16-19, 22, 27, 29-36, and 41 be entered in order to avoid this application incurring a surcharge for the present of one or more multiple dependent claims.

Respectfully submitted,

Date September 24, 2001

By Michele M Simkin

Michele M. Simkin
Attorney for Applicant
Registration No. 34,717

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5538
Facsimile: (202) 672-5399

VERSION WITH MARKING TO SHOW CHANGES MADE

4. (Amended) A retroviral vector according to claim 1 [or claim 2 or claim 3] wherein the retroviral vector further comprises a second NOI; wherein the secomd NOI is downstream of the FSAS.

6. (Amended) A retroviral vector according to claim 4 [or claim 5] wherein the second NOI, or the expression product thereof, is or comprises a therapeutic agent or a diagnostic agent.

7. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the first NOI. or the expression product thereof, is or comprises any one or more of an agent conferring selectability (e.g. a marker element), a viral essential element. or a part thereof, or combinations thereof.

8. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the first NS is at or near to the 3′ end of a retroviral pro-vector; preferably wherein the 3′ end comprises a U3 region and an R region; and preferably wherein the first NS is located between the U3 region and the R region.

10. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the first NS is obtainable from a virus.

13. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the retroviral pro-vector comprises a retroviral packaging signal; and wherein the second NS is located downstream of the retroviral packaging signal such that splicing is preventable at a primary target site.

16. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the second NS is placed downstream of the first NOI such that the first NOI is capable of being expressed at a primary target site.

17. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the second NS is placed downstream of the first NOI such that the first NOI is capable of being expressed at a primary target site and the retroviral vector titre is enhanced.

18. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the second NS is placed upstream of a multiple cloning site such that one or more additional NOIs may be inserted.

19. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the second NS is a nucleotide sequence coding for an immunological molecule or a part thereof.

22. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the vector additionally comprises a functional intron.

27. (Amended) A retroviral vector according to claim 1 [any one of the preceding claims] wherein the vector or pro-vector is derivable from a murine oncoretrovirus or a lentivirus.

29. (Amended) A retroviral vector as defined in claim 1 [any one of the preceding claims] wherein the retroviral vector is an integrated provirus.

30. (Amended) A retroviral particle obtainable from a retroviral vector according to claim 1 [any one of the preceding claims].

31. (Amended) A cell transfected or transduced with a retroviral vector according to claim 1 [any one of claims 1-29 or a retroviral particle according to claim 30].

32. (Amended) A retroviral vector according to claim 1 [any one of claims 1-29 or a viral particle according to claim 30 or a cell according to claim 31 for use in medicine].

33. (Amended) Use of a retroviral vector in claim 1 [any one of claims 1 to 29 or a viral particle according to claim 30 or a cell according to claim 31] for the manufacture of a pharmaceutical composition to deliver one or more NOIs to a target site in need of same.

34. (Amended) A method comprising transfecting or transducing a cell with a retroviral vector according to claim 1 [any one of claims 1 to 29 or a viral particle according to claim 30 or by use of a cell according to claim 31].

35. (Amended) A delivery system for a retroviral vector according to claim 1 [any one of claims 1 to 29 a viral particle according to claim 30 or a cell according to claim 31] wherein the delivery system comprises one or more non-retroviral expression vector(s), adenoviruses(s), or plasmid(s) or combinations thereof for delivery of an NOI or a plurality of NOIs to a first target cell and retroviral vector for delivery of an NOI or a plurality of NOIs to a second target cell.

36. (Amended) A retroviral pro-vector as defined in claim 1 [any one of the preceding claims].

41. (Amended) Use of a hybrid viral vector system according to claim 39 [and claim 40] wherein the lentiviral vector ahs a split-intron configuration.